Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial

31 August 2026 (09:15 - 09:30)

Organised by:

About the speaker

Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail

Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial

Professor I. Hilgendorf (Berlin, DE)

Presentation thumbnail

Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study

Doctor D. Zhu (Beijing, CN)

Presentation thumbnail

Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial

Doctor K. Oyama (Sendai, JP)

Presentation thumbnail

A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)

Doctor Z. Tian (Beijing, CN)

Presentation thumbnail

Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)

Professor S. Nissen (Cleveland, US)

Access the full session

Session thumbnail

Beyond statins: the next wave of lipid-lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET

You may be interested in

Congress Presentation

Carotid plaques stabilization and regression with evolocumab

1 September 2025

Congress Presentation

Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study

1 September 2025

Congress Presentation

Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial

2 September 2024

Webinar

Update of the 2019 ESC Guidelines on Management of Dyslipidaemia: new recommendations and their impact on clinical practice

25 November 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources